Home » Stocks » BLUE

Bluebird Bio, Inc. (BLUE)

Stock Price: $46.98 USD 0.79 (1.71%)
Updated December 3, 4:00 PM EST - Market closed
Pre-market: $46.57 -0.41 (-0.87%) Dec 4, 8:00 AM

BLUE Stock Price Chart

Key Info

Market Cap 3.12B
Revenue (ttm) 250.02M
Net Income (ttm) -642.17M
Shares Out 66.25M
EPS (ttm) -10.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $46.98
Previous Close $46.19
Change ($) 0.79
Change (%) 1.71%
Day's Open 46.08
Day's Range 45.90 - 47.49
Day's Volume 577,191
52-Week Range 40.39 - 98.04

BLUE Stock News

GuruFocus - 6 days ago

It's a little-known company with lots going against it, but bluebird bio, Inc (NASDAQ:BLUE) has attracted investments from seven of the investing gurus followed by GuruFocus (and yes, the comp...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data prese...

The Motley Fool - 2 weeks ago

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Other stocks mentioned: ADPT, BPMC, NVAX, RHHBY
Newsfile Corp - 3 weeks ago

Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal sec...

PRNewsWire - 3 weeks ago

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advi...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen ...

The Motley Fool - 4 weeks ago

Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.

The Motley Fool - 4 weeks ago

A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.

Zacks Investment Research - 4 weeks ago

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Market Watch - 4 weeks ago

Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatm...

Investors Business Daily - 4 weeks ago

Bluebird Bio announced a delay for a gene therapy in treating sickle cell disease, leading BLUE stock to tumble early Thursday. Now, the company expects to ask for approval in late 2022.

Business Wire - 4 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta...

Zacks Investment Research - 4 weeks ago

Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 4 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent o...

Insider Monkey - 1 month ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

InvestorPlace - 1 month ago

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

Other stocks mentioned: ABBV, AMGN, BMY, MBIO, REGN, VRTX
Zacks Investment Research - 1 month ago

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 1 month ago

On Oct. 19, I reviewed three of the 10 companies a Jeffries health care analyst thinks are most likely to be acquired by members of Big Pharma. Now let's look at numbers four through six on th...

Other stocks mentioned: BMY
Benzinga - 1 month ago

Shares of bluebird bio Inc (NASDAQ: BLUE) are undervalued when weighed against the company's fundamentals, according to a Mizuho Securities analyst.  The Bluebird Bio Analyst: Difei Yang initi...

Zacks Investment Research - 1 month ago

bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

The Motley Fool - 2 months ago

The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.

Other stocks mentioned: EXAS
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday,...

Seeking Alpha - 2 months ago

bluebird bio Should Be On Your Radar With Multiple Catalysts Expected This Year And 2021

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111...

Investors Business Daily - 2 months ago

The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BLUE stock popped. T...

Other stocks mentioned: BMY
Business Wire - 2 months ago

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtag...

Other stocks mentioned: BMY
The Motley Fool - 2 months ago

bluebird bio hasn't performed well in the stock market of late. Do the biotech's recent woes make this a good opportunity for investors to buy its shares?

Zacks Investment Research - 2 months ago

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio to present new data from clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy at the 46th EBMT Annual Meeting.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.

Benzinga - 3 months ago

Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year.

Zacks Investment Research - 3 months ago

Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.

Zacks Investment Research - 3 months ago

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.

Zacks Investment Research - 4 months ago

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

PRINCETON, N.J., & CAMBRIDGE, Mass.

Other stocks mentioned: BMY
The Motley Fool - 5 months ago

Both of these biotech companies recently released encouraging data from clinical trials.

Other stocks mentioned: CRSP
Zacks Investment Research - 5 months ago

bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 5 months ago

bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.

The Motley Fool - 5 months ago

Patients in its clinical trial continue to be nearly free of the disease's most serious symptoms.

The Motley Fool - 5 months ago

Which of these two biotech companies is the better stock pick today?

Other stocks mentioned: GILD
Zacks Investment Research - 5 months ago

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor in bluebird bio.

Zacks Investment Research - 6 months ago

Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Motley Fool - 6 months ago

Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.

Market Watch - 6 months ago

Shares of Bluebird Bio Inc. BLUE, +4.80% fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400 million worth of common stock.

About BLUE

bluebird bio, a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaborat... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2013
Employees
1,171
Stock Exchange
NASDAQ
Ticker Symbol
BLUE
Full Company Profile

Financial Performance

In 2019, Bluebird Bio's revenue was $44.67 million, a decrease of -18.15% compared to the previous year's $54.58 million. Losses were -$789.61 million, 42.1% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Bluebird Bio is 80.95, which is an increase of 72.31% from the latest price.

Price Target
$80.95
(72.31% upside)